Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Summary

The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:

* Main indicators: the eradication rate of Helicobacter pylori for eradication.
* Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.

Conditions

• the Eradication Rates of Helicobacter Pylori

Interventions

DRUG

Rabeprazloe+bismuth+amoxicillin+clarithromycin

PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.

DRUG

Vonoprazan+amoxicillin+clarithromycin 14 days

VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.

DRUG

Vonoprazan+amoxicillin+clarithromycin 7 days

VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.

DRUG

Vonoprazan+tetracycline+furazolidone 14 days

VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.

DRUG

Vonoprazan+tetracycline+furazolidone 7 days

VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.

DRUG

Vonoprazan+amoxicillin+furazolidone 7 days

hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.

DRUG

Vonoprazan+amoxicillin+tetracycline 14 days

hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.

DRUG

Vonoprazan+amoxicillin 7 days

hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.

DRUG

Vonoprazan+amoxicillin 14 days

hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.

Sponsors & Collaborators

• Xijing Hospital of Digestive Diseases

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-09-04

Primary Completion

2024-11-25

Completion

2024-12-25

Countries

• China

Study Locations